Key Takeaways
- Atomic Alchemy, Oklo’s fully-owned subsidiary, obtained its inaugural NRC materials license for isotope handling, processing, and distribution at its Idaho facility.
- This approval creates Oklo’s first commercial revenue opportunity through isotope sales from the Idaho Radiochemistry Laboratory.
- This license is separate from Oklo’s primary advanced reactor projects, which remain pending NRC authorization before power generation can commence.
- A concurrent announcement revealed Oklo’s new partnership agreement with the U.S. Department of Energy for its inaugural reactor deployment at Idaho National Laboratory.
- Shares climbed 4.6% during premarket hours on Tuesday, with quarterly earnings scheduled for release after market close.
On Tuesday, Oklo achieved a significant regulatory victory, albeit with an important distinction. The Nuclear Regulatory Commission awarded its first materials license—though notably, the approval went to Atomic Alchemy, a wholly-owned subsidiary that Oklo acquired in 2025, rather than to the parent company directly.
This authorization permits Atomic Alchemy to accept, store, handle, and sell isotopes through its Idaho Radiochemistry Laboratory located in Idaho Falls. The license specifically covers up to 2 Curies of Radium-226, plus Cobalt-60 and Americium-241 for calibration applications.
These isotopes serve critical functions in medical applications, scientific research, industrial manufacturing, and national defense sectors. Oklo’s CEO Jacob DeWitte addressed the market gap directly: “Demand for critical isotopes is rising, but U.S. supply remains limited.”
The business implications are tangible and immediate. With this licensing approval, Atomic Alchemy can launch commercial isotope sales from its Idaho laboratory—representing the first revenue-generating capability within Oklo’s portfolio. Currently, the parent company has yet to record any revenue.
Crucially, investors should understand that this license differs entirely from the reactor authorization that markets have been anticipating. Oklo’s advanced fast reactor technology continues navigating the NRC approval pathway. Until that separate clearance arrives, the company cannot commercialize electricity generation—which represents its primary long-term business model.
Scope and Implications of the New License
The regulatory approval followed comprehensive review procedures and an on-location inspection of the Idaho operations. Atomic Alchemy’s strategy involves recovering and reprocessing retired radium sources—materials historically classified as waste—converting them into valuable feedstock for medical isotope manufacturing, particularly for targeted alpha therapy applications.
Beyond immediate operations, this laboratory serves as groundwork for larger ambitions. Atomic Alchemy is engineering a multi-reactor isotope production facility featuring up to four Versatile Isotope Production Reactor (VIPR) units, each designed for approximately 15 MWth output capacity.
Tuesday’s announcements included a second development. Oklo formalized an agreement with the U.S. Department of Energy covering design, construction, and operational support for its debut reactor at Idaho National Laboratory through the DOE’s Reactor Pilot Program initiative.
The Meta Partnership and Earnings Expectations
Oklo’s nuclear energy vision has attracted substantial corporate interest. A notable partnership with Meta Platforms involves developing a nuclear energy campus in Ohio’s southeastern region. BofA Securities characterized this arrangement as “one of a few firm, binding partnerships today” within the emerging nuclear sector.
Shares appreciated 4.6% in premarket activity Tuesday as market participants evaluated the regulatory milestone. The company’s quarterly financial results are scheduled for release after the closing bell on the same day.
Oklo maintains its target timeline for commercial nuclear power delivery between late 2027 and 2028.
